ACEi, ARB, Or ARNI Therapy Reduces Readmissions In Patients With Heart Failure With Reduced Ejection Fraction And Chronic Kidney Disease Stages IV Or V
Nicholas Faraci,Bradley Very,Joseph Ibrahim,Floyd Thoma,Ahmet Sezer,Gavin Hickey
DOI: https://doi.org/10.1016/j.cardfail.2023.10.221
IF: 6.592
2024-01-01
Journal of Cardiac Failure
Abstract:Introduction Heart failure with reduced ejection fraction (HFrEF) often occurs concurrently with chronic kidney disease (CKD) and end-stage renal disease (ESRD). The benefits of angiotensin converting enzyme inhibitors (ACEi), angiotensin receptor blockers (ARB), and angiotensin receptor/neprilysin inhibitors (ARNI) are well established in both HFrEF and CKD. However, there is little evidence on the effect of these therapies in patients with concomitant HFrEF and CKD stages IV or V. Hypothesis In patients with HFrEF and CKD IV or V, discharge on ACEi, ARB, or ARNI is associated with reduced mortality and heart failure (HF) readmissions compared to patients discharged without these therapies. Methods Retrospective cross-sectional observational analysis of 1,352 patients admitted for HF between 2018 and 2022 at a tertiary academic center. Patients with an EF of 40% or less and a GFR less than 30mL/min or ESRD diagnosis were included. Patients discharged on ACEi, ARB, or ARNI, were compared to patients without ACEi, ARB, or ARNI. Baseline clinical characteristics were calculated as a frequency (%) for categorical variables and a mean (ds) for continuous variables and compared using the Pearson chi-square test and t-test, respectively. Groups were propensity-matched 1:1 based on clinical variables including age, gender, race, ADI, walkscore, EF, COPD, diabetes, hypertension, and other discharge guideline-directed medical therapy (i.e. beta blocker, MRA, SGLT2). The threshold for statistical significance was 2-sided with a type I error rate of 0.05. The primary and secondary outcome were mortality and HF readmission at 1 and 2 years, respectively. Results There were 201 patients each in the treatment and control groups. Average EF for the treatment and control groups were 29.61±8.26 and 29.94±7.95 (p = 0.6823), respectively. Approximately 46% of the treatment group and 27% of the control group required dialysis. The Charlson comorbidity index for the treatment group was 4.22±2.1 and 4.19±2.34 for the control group (p = 0.8755). The treatment group had significantly reduced rates of HF readmissions when compared to the control group at 2 years (p = 0.0106). The treatment group also had lower mortality rates at 2 years compared to the control group, but this difference did not reach statistical significance (p = 0.0597). Conclusion ACEi, ARB, and ARNI therapy on discharge was associated with a significant reduction in HF readmissions in patients with HFrEF and CKD IV or V admitted with a HF exacerbation. There was a reduction in mortality that approached but did not reach significance.
cardiac & cardiovascular systems